Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.

Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.

Abstract: The present invention provides antibodies, that bind to human CEACAM6 and are able to relieve CEACAM6-mediated immunosuppression, wherein said antibodies have reduced side-effects during treatment. The present invention further provides isolated nucleic acids encoding said antibodies and vectors comprising same, isolated cells expressing said antibodies, methods of producing said antibodies and pharmaceutical compositions and kits comprising said antibodies. Antibodies according to the present invention can be used to treat cancer and might be used to treat other disorders and conditions associated with the expression of the CEACAM6.

Abstract: The present invention is related to agents capable of binding to and inhibiting or antagonizing the action of IL-11 and/or IL-11RA for the treatment and/or prevention of abnormal uterine bleeding, which comprises heavy menstrual bleeding, prolonged bleeding, altered bleeding pattern, dysmenorrhea, as well as of the underlying diseases leiomyoma and endometriosis and the use of the agent to inhibit menstruation. Furthermore, the invention provides novel IL-11 antibodies.

Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.

Abstract: The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Sema3A. The isolated antibody or antigen-binding fragment according to the present disclosure i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD)?50 nM, ?20 nM, ?10 nM, ?1 nM, or ?0.1 nM; ii) cross-reacts with mouse, cynomolgus, rat, pig and/or dog Sema3A, particularly wherein said isolated antibody or antigen-binding fragment thereof binds to mouse, cynomolgus, rat, pig and/or dog Sema3A with a dissociation constant (KD)?50 nM, ?20 nM, ?10 nM, ?1 nM, or ?0.1 nM; iii) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a binding activity as measured by surface plasmon resonance (SPR) of ?60%, ?70%, ?80%, or ?90%; iv) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro mesangial cell migration assay with an EC50 of ?10 nM, ?5 nM, ?2.

Abstract: The present invention is related to agents capable of binding to and inhibiting or antagonizing the action of IL-11 and/or or IL-11RA for the treatment and/or prevention of abnormal uterine bleeding, which comprises heavy menstrual bleeding, prolonged bleeding, altered bleeding pattern, dysmenorrhea, as well as of the underlying diseases leiomyoma and endometriosis and the use of the agent to inhibit menstruation. Furthermore, the invention provides novel IL-11 antibodies.

Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.

Abstract: The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Sema3A. The isolated antibody or antigen-binding fragment according to the present disclosure i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD)?50 nM, ?20 nM, ?10 nM, ?1 nM, or ?0.1 nM; ii) cross-reacts with mouse, cynomolgus, rat, pig and/or dog Sema3A, particularly wherein said isolated antibody or antigen-binding fragment thereof binds to mouse, cynomolgus, rat, pig and/or dog Sema3A with a dissociation constant (KD)?50 nM, ?20 nM, ?10 nM, ?1 nM, or ?0.1 nM; iii) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a binding activity as measured by surface plasmon resonance (SPR) of ?60%, ?70%, ?80%, or ?90%; iv) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro mesangial cell migration assay with an EC50 of ?10 nM, ?5 nM, ?2.

Abstract: Described herein are methods and means for reliably releasing maternal and/or paternal DNA from single seeds without substantially affecting the subsequent germination of the seeds. The methods are particularly suited for genome analysis of small grain cereals, including wheat. The methods may include enzymatic treatments for improved DNA recovery.

Abstract: A computer-implemented method for providing a lens shape for an ophthalmic lens is disclosed. Further, there is provided a method for angular smoothing of a surface determined by carrier lines radially outwards of a prescription zone bordered by a first boundary line. In addition, there is provided an ophthalmic lens, in particular, a spectacle lens. Moreover, a method for minimizing the difference in thickness between two ophthalmic lenses for the same spectacles is provided. A computer program product and a machine-readable storage medium are provided as well.

Abstract: A manufacturing method for manufacturing a spectacle lens is disclosed. The method includes: obtaining prescription data descriptive of an ophthalmic prescription of a user in the plus prescription range; obtaining frame data descriptive of a perimeter of a spectacle frame in which the lens is to be mounted; providing a lens blank having a convex front surface and a back surface; determining a final cutting surface to be machined on the back surface of the lens blank in a final cutting phase; and determining an intermediate cutting surface to be machined on the back surface of the lens blank in an initial cutting phase. Further, it is provided that the intermediate cutting surface is different from the final cutting surface; and the final cutting surface comprises a prescription zone in which the final cutting surface together with the front surface fulfills the ophthalmic prescription of the user.

Abstract: The current invention is directed to a computer-implemented method for providing a lens shape for an ophthalmic lens. Further, there is provided a method for angular smoothing of a surface determined by carrier lines radially outwards of a prescription zone bordered by a first boundary line. Further, there is provided an ophthalmic lens, in particular a spectacle lens. Further, a method for minimizing the difference in thickness between two ophthalmic lenses for the same spectacles. A computer program product and a machine readable storage medium are provided as well.

Abstract: A computer-implemented method for providing a lens shape for an ophthalmic lens is disclosed. Further, there is provided a method for angular smoothing of a surface determined by carrier lines radially outwards of a prescription zone bordered by a first boundary line. In addition, there is provided an ophthalmic lens, in particular, a spectacle lens. Moreover, a method for minimizing the difference in thickness between two ophthalmic lenses for the same spectacles is provided. A computer program product and a machine-readable storage medium are provided as well.

Abstract: A computer-implemented method for providing a lens shape for an ophthalmic lens is disclosed. Further, there is provided a method for angular smoothing of a surface determined by carrier lines radially outwards of a prescription zone bordered by a first boundary line. In addition, there is provided an ophthalmic lens, in particular, a spectacle lens. Moreover, a method for minimizing the difference in thickness between two ophthalmic lenses for the same spectacles is provided. A computer program product and a machine-readable storage medium are provided as well.

Abstract: A manufacturing method for manufacturing a spectacle lens is disclosed. The method includes: obtaining prescription data descriptive of an ophthalmic prescription of a user in the plus prescription range; obtaining frame data descriptive of a perimeter of a spectacle frame in which the lens is to be mounted; providing a lens blank having a convex front surface and a back surface; determining a final cutting surface to be machined on the back surface of the lens blank in a final cutting phase; and determining an intermediate cutting surface to be machined on the back surface of the lens blank in an initial cutting phase. Further, it is provided that the intermediate cutting surface is different from the final cutting surface; and the final cutting surface comprises a prescription zone in which the final cutting surface together with the front surface fulfills the ophthalmic prescription of the user.

Abstract: A computer-implemented method for providing a lens shape for an ophthalmic lens is disclosed. Further, there is provided a method for angular smoothing of a surface determined by carrier lines radially outwards of a prescription zone bordered by a first boundary line. In addition, there is provided an ophthalmic lens, in particular, a spectacle lens. Moreover, a method for minimizing the difference in thickness between two ophthalmic lenses for the same spectacles is provided. A computer program product and a machine-readable storage medium are provided as well.

Abstract: Described herein are methods and means for reliably releasing maternal and/or paternal DNA from single seeds without substantially affecting the subsequent germination of the seeds. The methods are particularly suited for genome analysis of small grain cereals, including wheat. The methods may include enzymatic treatments for improved DNA recovery.

Abstract: A computer-implemented method for providing a lens shape for an ophthalmic lens is disclosed. Further, there is provided a method for angular smoothing of a surface determined by carrier lines radially outwards of a prescription zone bordered by a first boundary line. In addition, there is provided an ophthalmic lens, in particular, a spectacle lens. Moreover, a method for minimizing the difference in thickness between two ophthalmic lenses for the same spectacles is provided. A computer program product and a machine-readable storage medium are provided as well.

Abstract: A computer-implemented method for providing a lens shape for an ophthalmic lens is disclosed. Further, there is provided a method for angular smoothing of a surface determined by carrier lines radially outwards of a prescription zone bordered by a first boundary line. In addition, there is provided an ophthalmic lens, in particular, a spectacle lens. Moreover, a method for minimizing the difference in thickness between two ophthalmic lenses for the same spectacles is provided. A computer program product and a machine-readable storage medium are provided as well.